Judith Trotman
Medicine
University of Sydney
Australia
Biography
Associate Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is a Senior Staff Specialist and Director, Clinical Research Unit in the Haematology Department, Concord Hospital. With a particular interest in lymphoma care, she has built a broad portfolio of trials across the spectrum of lymphoid malignancies, accessing emerging new therapies for patients from across NSW. Dr Trotman worked as a scholar and clinician in 2009-2010 in the Clinical Research Unit in Lyon, France, within LYSA, the world leading French lymphoma trials collaborative. Her own research demonstrating the predictive power of PET-CT response assessment after first-line therapy in PRIMA, the worlds largest clinical trial in Follicular Lymphoma, has impacted on NCCN guidelines and was recently published in the Journal of Clinical Oncology. Dr Trotman returned to Concord convinced that we have the capacity to build a comprehensive lymphoma research portfolio and deliver World class care, Locally. Committed to both Australian based research and international collaborations she is a member of the ALLG (Australian Leukaemia and Lymphoma Group) Scientific Advisory Committee and the Chair of the Low Grade Lymphoma Committee,and Principal Investigator for two international studies: the UK led, NHMRC funded, Response Adapted Therapy in Hodgkin Lymphoma study (RATHL-HD8), publishe in NEJM 2016 and the French led, REMARC-NHL25 study of Lenalidomide maintenance for older patients with diffuse large B cell lymphoma. She is also the Principal Investigator in the international FOLLCOLL study of PET scanning in Follicular Lymphoma, and of an ALLG world-first study of PET-adapted therapy for patients with relapsed Follicular Lymphoma, and a novel study of Ibrutinib plus miniRCHOP in very elderly patients with DLBCL. Other national research collaborations include the pharmacokinetics of High Dose Melphalan, the chemotherapy conditioning regimen used before autologous transplantation in Myeloma. She is coinventor of ClinTrial Refer, a smartphone and tablet App that has facilitated increased collaboration in cross-referral and recruitment to clinical trials across 17 research portfolios internationally. She has published extensively in leading journals including NEJM, Blood, Journal of Clinical Oncology and The Lancet Haematology. Awarded Best Lecturer Year 1 at Concord 2015 she has supervised Honours and MD student theses. Associate Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is a Senior Staff Specialist and Director, Clinical Research Unit in the Haematology Department, Concord Hospital. With a particular interest in lymphoma care, she has built a broad portfolio of trials across the spectrum of lymphoid malignancies, accessing emerging new therapies for patients from across NSW. Dr Trotman worked as a scholar and clinician in 2009-2010 in the Clinical Research Unit in Lyon, France, within LYSA, the world leading French lymphoma trials collaborative. Her own research demonstrating the predictive power of PET-CT response assessment after first-line therapy in PRIMA, the worlds largest clinical trial in Follicular Lymphoma, has impacted on NCCN guidelines and was recently published in the Journal of Clinical Oncology. Dr Trotman returned to Concord convinced that we have the capacity to build a comprehensive lymphoma research portfolio and deliver World class care, Locally. Committed to both Australian based research and international collaborations she is a member of the ALLG (Australian Leukaemia and Lymphoma Group) Scientific Advisory Committee and the Chair of the Low Grade Lymphoma Committee,and Principal Investigator for two international studies: the UK led, NHMRC funded, Response Adapted Therapy in Hodgkin Lymphoma study (RATHL-HD8), publishe in NEJM 2016 and the French led, REMARC-NHL25 study of Lenalidomide maintenance for older patients with diffuse large B cell lymphoma. She is also the Principal Investigator in the international FOLLCOLL study of PET scanning in Follicular Lymphoma, and of an ALLG world-first study of PET-adapted therapy for patients with relapsed Follicular Lymphoma, and a novel study of Ibrutinib plus miniRCHOP in very elderly patients with DLBCL. Other national research collaborations include the pharmacokinetics of High Dose Melphalan, the chemotherapy conditioning regimen used before autologous transplantation in Myeloma. She is coinventor of ClinTrial Refer, a smartphone and tablet App that has facilitated increased collaboration in cross-referral and recruitment to clinical trials across 17 research portfolios internationally. She has published extensively in leading journals including NEJM, Blood, Journal of Clinical Oncology and The Lancet Haematology. Awarded Best Lecturer Year 1 at Concord 2015 she has supervised Honours and MD student theses.
Research Interest
Lymphoproliferative diseases. Myeloma Multidisciplinary care
